Merck KGaA boasts five-pronged innovation assault

German life sciences major Merck KGaA’s (MRK: DE) Healthcare unit has provided an update on its innovative pipeline.

The pipeline’s focus is on five mid- to late-stage assets with first-in-class or best-in-class potential, which the company is confident will help to deliver significant long-term growth.

One of the most exciting of these assets is evobrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi) with a new mechanism of action for the treatment of patients with relapsing multiple sclerosis (RMS) that has the potential to change the standard of care. There is comprehensive Phase II data to support its best-in-class potential.